Anticoagulation with heparin

ApprovedSmall molecule

Anticoagulation with heparin is one of 40 small molecule programs targeting Pulmonary Embolism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismActive, not recruiting

Pulmonary EmbolismApproved

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Pulmonary Embolism

#DrugCompanyPhaseTrials

Innohep

Alnylam Pharmaceuticals

Approved

1 2

Savaysa

Daiichi Sankyo

Approved

—3

Unfractionated Heparin

GSK

Approved

3 4

Activase

Roche

Phase 3

7 5

Tnkase

Roche

Phase 3

2 6

Heparin Sodium

BBaxter Healthcare Corporation

Phase 3

2 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Phase 3

4 8

Acenocoumarol

Roche

Approved

1 9

Lovenox

Sanofi

Phase 2

6 10

Recombinant Tissue Plasminogen Activator

BBoston Scientific Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

ApprovedActive, not recruiting

Pulmonary Embolism

NCT04790370

Clinical

Trials by Indication[1]

Pulmonary Embolism1 trial

A Randomized Trial of Ultrasound-facilitated, Catheter-directed, Thrombolysis Versus Anticoagulation for Acute Intermediate-high Risk Pulmonary Embolism: The Higher-risk Pulmonary Embolism Thrombolysis Study

Active, not recruiting·BBoston Scientific Corporation·Approved·NCT04790370·544 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anticoagulation with heparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticoagulation with heparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticoagulation with heparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Scientific Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBoston Scientific Corporation

Anticoagulation with heparin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Pulmonary Embolism1 trial

References

Drug Info

Quick Facts

Related News